scholarly journals The impact of the pharmaceutical care management model of hepatitis C medications on the cost at the health insurance level

2019 ◽  
Vol 16 ◽  
pp. 165
Author(s):  
Fadia B. Al Mahdi ◽  
Almoutaz H. Hashim ◽  
Emad Aldin M. Albaba ◽  
Ohoud N. Salih ◽  
Reem J. Alkasam ◽  
...  
Keyword(s):  
Health Insurance ◽  
Hepatitis C ◽  
Pharmaceutical Care ◽  
Care Management ◽  
Management Model ◽  
The Cost ◽  
The Impact

scholarly journals The Impact of the Pharmaceutical Care Management Model of Hepatitis C Medications on the Cost at Health Insurance Level

2020 ◽  
Vol 21 ◽  
pp. 230-237
Author(s):  
Fadia B. Almahdi ◽  
Almoutaz H. Hashim ◽  
Emad Aldin M. Albaba ◽  
Ohoud N. Salih ◽  
Reem J. Alkasam ◽  
...  
Keyword(s):  
Health Insurance ◽  
Hepatitis C ◽  
Pharmaceutical Care ◽  
Care Management ◽  
Management Model ◽  
The Cost ◽  
The Impact

scholarly journals Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e035224
Author(s):  
Haoya Yun ◽  
Guoqiang Zhao ◽  
Xiaojie Sun ◽  
Lizheng Shi
Keyword(s):  
Sensitivity Analysis ◽  
Hepatitis C ◽  
Cost Effective ◽  
Cost Utility ◽  
Direct Acting Antivirals ◽  
Lifetime Horizon ◽  
System Perspective ◽  
Direct Acting ◽  
The Cost ◽  
The Impact

ObjectiveThis study aimed to estimate the cost–utility of sofosbuvir/velpatasvir (SOF/VEL) compared with other direct-acting antivirals (DAAs) in Chinese patients with hepatitis C virus (HCV).DesignA Markov model was developed to estimate the disease progression of patients with HCV over a lifetime horizon from the healthcare system perspective. Efficacy, clinical inputs and utilities were derived from the published literature. Drug costs were from the market price survey, and health costs for Markov health states were sourced from a Chinese study. Costs and utilities were discounted at an annual rate of 5%. One-way and probabilistic sensitivity analyses were conducted to test the impact of input parameters on the results.InterventionsSOF/VEL was compared with sofosbuvir+ribavirin (SR), sofosbuvir+dasabuvir (SD), daclatasvir+asunaprevir (DCV/ASV), ombitasvir/paritaprevir/ritonavir+dasabuvir (3D) and elbasvir/grazoprevir (EBR/GZR).Primary and secondary outcomesCosts, quality-adjusted life years (QALYs) and incremental cost–utility ratios (ICURs).ResultsSOF/VEL was economically dominant over SR and SD. However, 3D was economically dominant compared with SOF/VEL. Compared with DCV/ASV, SOF/VEL was cost-effective with the ICUR of US$1522 per QALY. Compared with EBR/GZR, it was not cost-effective with the ICUR of US$369 627 per QALY. One-way sensitivity analysis demonstrated that reducing the cost of SOF/VEL to the lower value of CI resulted in dominance over EBR/GZR and 3D. Probabilistic sensitivity analysis demonstrated that 3D was cost-effective in 100% of iterations in patients with genotype (GT) 1b and SOF/VEL was not cost-effective.ConclusionsCompared with other oral DAA agents, SOF/VEL treatment was not the most cost-effectiveness option for patients with chronic HCV GT1b in China. Lower the price of SOF/VEL will make it cost-effective while simplifying treatment and achieving the goal of HCV elimination.

scholarly journals PIN3 THE COST OF TREATING RIBAVIRIN-INDUCED ANEMIA IN HEPATITIS C: THE IMPACT OF USING RECOMBINANT HUMAN ERYTHROPOETIN

2006 ◽  
Vol 9 (3) ◽  
pp. A154
Author(s):  
JT Cross ◽  
EB Devine ◽  
KV Kowdley ◽  
SD Sullivan
Keyword(s):  
Hepatitis C ◽  
The Cost ◽  
The Impact

Introduction to Pharmaceutical Care and Medication Adherence

2021 ◽  
pp. 1-31
Keyword(s):  
Medication Adherence ◽  
Drug Interactions ◽  
Pharmaceutical Care ◽  
Intervention Strategies ◽  
Patients With Cancer ◽  
Alternative Medicines ◽  
Micro Level ◽  
The Cost ◽  
The Impact

Pharmaceutical care is a concept that involves identifying, solving and preventing drug-related problems, such as drug interactions, with regards to a patient's drug therapy. Cancer patients are at high risk of drug interactions due to the complex pharmacological profiles and narrow therapeutic indices of anticancer drugs. Furthermore, these patients tend to consume complementary and alternative medicines, thus predisposing them to a risk of herb-drug interactions. This can impact their adherence to anticancer therapies. Various factors are involved in medication non-adherence, such as the cost of medications and patients' beliefs about the value of their treatments. There is a need to understand the impact of non-adherence and optimize intervention strategies from a macro-, meso-, and micro-level. Chapter 1 introduces the concept of pharmaceutical care and the impact of oncology drug interactions and medication non-adherence in patients with cancer. The chapter will also provide an insight to the factors influencing medication adherence and the intervention strategies that have targeted non-adherence.

scholarly journals INTEGRATING ACUTE AND LONG-TERM SERVICES: DOES IT WORK, CAN IT WORK, WILL IT WORK?

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S229-S230
Author(s):  
Robert A Applebaum ◽  
Jennifer Heston
Keyword(s):  
Managed Care ◽  
Integrated Care ◽  
Care Management ◽  
Service Providers ◽  
Care Staff ◽  
Care Plan ◽  
Management Model ◽  
Management Models ◽  
The Impact

Abstract The expansion of managed long-term services and supports has generated considerable interest over the last decade. However, studies on the impact of these efforts have produced mixed findings. Additionally, there is limited information about the care management models used in implementation. This lack of data makes it impossible to assess whether differences in managed care plan approaches have an impact on participants. Our study sought to gain better understanding of the integrated care management models being implemented in Ohio’s MyCare Demonstration. Through qualitative interviews with 50 respondents, including area agency care managers, managed care staff, and service providers, we documented strengths and weaknesses of one integrated care management model used in Ohio’s demonstration. Understanding what is inside the black box of managed care/care management model implementation is key to gaining insights into whether such an approach can ultimately improve the health and long-term service systems for older people with disability.

Sign in / Sign up

Export Citation Format

Share Document